Worldwide, more than half a million new cases of hepatocellular carcinoma (HCC) are diagnosed annually. The incidence of HCC in the United States is rising with an estimated 31,000 new cases in 2018. Disease prognosis remains poor, with a 5-year survival rate across all disease stages estimated between 10%-20%, and 3% for those diagnosed with distant disease. Although morbidity is significant, especially among patients with advanced-stage disease, limited information exists on the humanistic and economic burden of HCC.
After Medicaid expansion in Michigan, appointment availability for new Medicaid patients stably increased-this is perhaps attributable to increasing proportions of appointments scheduled with nonphysician providers.
The speed and extent of biosimilar penetration differ across provider types. Provider awareness and incentives are significantly associated with biosimilar uptake.
Using a microsimulation approach, this study modeled the potential multiyear health and economic benefits of participating in cardiometabolic virtual-first care programs.
Cancer pathways can potentially improve patient outcomes and reduce costs. Recent concerns about pathway adoption deserve attention, including excessive administrative burden to clinics.
Automated phone and mail population outreach resulted in an almost 4-fold increase in the rate of screening for colorectal cancer even without an office visit.
Electronic health record data can be used to predict patient absenteeism accurately. Predictive overbooking of missed appointments can significantly increase service utilization.
Complex care management for high-need, high-cost Medicaid patients significantly reduced total medical expenditures and inpatient utilization in a randomized quality improvement trial.
This study evaluated the impact of a patient safety intervention and national guideline to reduce unnecessary red blood cell transfusions in a large, urban academic medical center.
Significant additional outreach and engagement strategies and incentives are likely required to increase adoption and ongoing use of health risk assessment tools among target populations.
Veterans with inflammatory bowel disease taking adalimumab appear to be more likely to remain on the drug 1 year after initiation than patients who are privately insured.
Evaluation of healthcare utilization and costs over 3 years for adults with insulin-requiring diabetes who transition from multiple daily insulin injections to insulin infusion pumps.
The impact of price changes in drugs, at least among previously adherent patients, was modest in size except for drugs with large price changes.
A payer—provider, patient registry to identify individuals with serious mental illness and chronic physical health conditions for utilization in behavioral health homes is described.